Tylenol Study Linking to Autism From Faulty Sources

Dr. Andrea Baccarelli, dean of Harvard’s T.H. Chan School of Public Health and formerly a professor at Columbia University, has come under scrutiny after it was revealed he was paid at least $150,000 to serve as an expert witness for plaintiffs suing Johnson & Johnson, the former manufacturer of Tylenol.

The plaintiffs, parents of children later diagnosed with autism or ADHD, alleged that maternal use of acetaminophen (Tylenol’s active ingredient) during pregnancy caused their children’s conditions. Baccarelli testified that “substantial evidence supports a strong, positive, causal association” between acetaminophen and neurodevelopmental disorders.

Federal Judge Denise Cote, however, dismissed the lawsuit, ruling that Baccarelli had “cherry-picked and misrepresented study results” while failing to account for genetic factors. His testimony was thrown out, and the case was dismissed, though it is now under appeal in the Second Circuit Court of Appeals.

Baccarelli confirmed to Scripps News that he also consulted with the Trump administration ahead of its recent autism policy announcement, which cited his research. But in a public statement, he tempered his position, noting that while evidence suggests a possible link between acetaminophen and neurodevelopmental disorders, causation has not been firmly established. He advised caution with heavy or prolonged use during pregnancy but emphasized the need for further research.

This stands in contrast to his stronger claims made in the lawsuit, where he omitted such cautions.

The Trump administration has leaned on Baccarelli’s work in suggesting stronger warnings on acetaminophen, framing it as a public health issue. However, dozens of medical and health groups have criticized these claims, warning that overstating risks without solid evidence could cause unnecessary panic among expectant mothers.

Kenvue, the current maker of Tylenol after Johnson & Johnson’s consumer health spinoff, issued a statement saying acetaminophen is safe when used as directed, rejecting any link to autism or ADHD.

Experts note that while it is not unusual for researchers to provide paid expert testimony, the amount Baccarelli received, coupled with the mismatch between his courtroom assertions and more measured scientific statements, has fueled debate over credibility and conflicts of interest.

Main Points

Dr. Andrea Baccarelli was paid $150,000 to testify in lawsuits alleging Tylenol use during pregnancy causes autism and ADHD.
His testimony claimed a strong causal link, but a federal judge dismissed it as misleading and selective.
The lawsuit against Johnson & Johnson was dismissed; appeals are ongoing.
Baccarelli also consulted with the Trump administration, which cited his research in recent autism policy moves.
His public statements now strike a more cautious tone, acknowledging uncertainty and the need for further research.
Medical groups and Kenvue reject the claims, emphasizing Tylenol’s safety when used properly.

Projections

Potential Positive Outcomes (Pro):

Heightened scrutiny may encourage more rigorous research into acetaminophen safety during pregnancy.
Could lead to clearer medical guidelines that balance caution with reassurance for expectant mothers.
Public debate may strengthen transparency standards for expert witnesses in litigation.

Potential Negative Outcomes (Con):

Misinformation risks: overstated or inconsistent claims may cause unwarranted fear among pregnant women, potentially deterring safe pain relief.
Politicization of autism research could undermine trust in public health messaging.
Perceived conflicts of interest may weaken confidence in legitimate scientific studies if researchers appear financially motivated.
Legal uncertainty from ongoing appeals may prolong confusion for both families and healthcare providers.

Sources

Denver7 / Scripps News – Scientist behind autism study cited by Trump admin paid $150K by plaintiffs suing Tylenol manufacturerdenver7.com
Court filings from SDNY (Judge Denise Cote’s ruling)
Statements from Kenvue and medical organizations opposing the claims